Viewing nowCombinationPimaten Tablets 60/2.5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceutical Co., Ltd.

MFDS item code 202300125 · Approved 2023.01.06 · Insurance code 654006050
Treatment of essential hypertension not controlled with fimasartan monotherapy
In patients with essential hypertension where blood pressure is not adequately controlled with monotherapy of pimasartan potassium, this medication helps to control blood pressure more effectively. This aids in maintaining stable blood pressure and reducing the risk of complications caused by hypertension. Therefore, it plays an important role in hypertension management.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended to take the tablet at the same time each day (e.g., in the morning), if possible. It is recommended that the dose be adjusted with fimasartan before administering this medicine. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams monotherapy. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams monotherapy. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams monotherapy or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used by patients with known allergies to any of its components, those who are pregnant or breastfeeding, patients undergoing kidney dialysis, those with severe liver dysfunction, bile duct obstruction, specific genetic metabolic disorders, severe aortic stenosis, or in a shock state. Caution is advised for patients with reduced blood volume or impaired kidney function, renal artery hypertensive patients, patients with certain heart diseases, severe hypotension, the elderly, and those with a history of allergy to any dyes included in this medication. Common side effects may include headache, dizziness, facial edema, urination disorders, insomnia, flushing, etc. Rarely, severe kidney problems, low blood pressure, or allergic reactions may occur. Blood pressure may drop too low while taking this medication, so if symptoms of hypotension occur, one should lie down and rest immediately, and may need intravenous treatment if necessary. There is a risk of elevated serum potassium levels, especially for patients with heart failure or kidney disease, so potassium levels should be regularly checked through blood tests. This medication may interact with other antihypertensives, diuretics, certain analgesics, lithium, ketoconazole, etc., so consultation with a doctor or pharmacist is essential if other medications are being taken. This medication may pose risks to the fetus during pregnancy, so those planning to become pregnant or currently pregnant should consult with healthcare professionals, and using this medication while breastfeeding is not recommended. Safety and efficacy has not been established for children under 18 years of age, so it should be avoided in this age group. No special dosage adjustment is needed for the elderly, but caution is necessary as they may respond more sensitively. This medication should not be administered to patients with severe liver dysfunction. In cases of overdose, symptoms such as hypotension, arrhythmias, and shock may occur; immediate medical attention is required for appropriate treatment. This medication should be kept out of reach of children and should not be transferred to another container, as it may affect its quality.
Dizziness, orthostatic dizziness, headache, facial swelling, peripheral edema, urinary disorders, insomnia, flushing, syncope, sedation, migraine, dyspepsia, vomiting, nausea, upper abdominal pain, weakness, foreign body sensation, elevated liver enzyme levels, decreased platelet count, increased serum creatine phosphokinase, cough, muscle contractions, musculoskeletal stiffness, pruritus, localized urticaria, facial flushing, erectile dysfunction, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuronitis, facial paralysis, normal pressure hydrocephalus, spinal stenosis, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, worsening cerebral infarction, cerebral hemorrhage, liver cancer, colorectal cancer, neoplasm of unspecified type, cervical cancer, prostate cancer, acute kidney failure, chronic kidney failure, kidney stones, pyelonephritis, urinary incontinence, rhinitis, fibrosing alveolitis, pharyngitis, pneumonia, lung disease, death, worsening low back pain, osteoarthritis, arthropathy, hypoglycemia, hyperkalemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, increased blood pressure, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, cerebral infarction, fracture, chest pain, weakness, fatigue, pain, weight gain, weight loss, hypotension, vasculitis, tension hyperactivity, sensory decrease, sensory abnormality, peripheral neuropathy, taste disturbance, tremor, extrapyramidal disorder, gynecomastia, change in bowel habits, dry mouth, dyspepsia, gingival hypertrophy, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, dyspnea, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, nocturia, hepatitis, jaundice, elevation of liver enzyme levels, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin erythema, papular rash, heaviness, warmth, impaired glucose tolerance, weakness, symptoms of hypotension due to volume and sodium depletion, increased serum potassium levels, increased serum creatinine, increased blood urea, acute kidney failure, shock symptoms, loss of consciousness, dyspnea, severe hypotension, drowsiness, pulmonary edema, decreased blood pressure, blood pressure fluctuations, increased blood pressure, purpura, fatty liver, severe hypotension, need for vasoconstrictors, need for intravenous calcium gluconate administration
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a light-proof container. Additionally, it is important to keep it at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.
Yellow, rectangular, film-coated tablet with rounded edges
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.